Puma Biotech Q1 net income $1.4M vs loss; NERLYNX revenue $46.8M (+15% YoY)

PUMA BIOTECHNOLOGY, INC.

2022-Q1 EPS reported $0.03 revenue$52,775,000

GAAP net income $1.4M ($0.03/diluted share) vs net loss of $3.4M in Q1 2022.
Non-GAAP adjusted net income $4.2M ($0.09/share) vs adjusted net loss of $0.3M.
Q1 product revenue (NERLYNX) $46.8M, up from $40.7M YoY; royalty revenue $6.0M.
Cash and marketable securities $71.2M at March 31, 2023 vs $81.1M at Dec 31, 2022.
Guidance: FY 2023 net product revenue $205-210M; net income $20-24M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PUMA BIOTECHNOLOGY, INC. reported first quarter ended March 31, 2023 results: revenue $46.8 million, net income $1.4 million, EPS $0.03 per basic and diluted share.

Period: first quarter ended March 31, 2023
Revenue: $46.8 million
Net income: $1.4 million
EPS: $0.03 per basic and diluted share
Result: reported results

Exact text from the filing

Product revenue, net in the first quarter of 2023 was $46.8 million, compared to product revenue, net of $40.7 million in the first quarter of 2022. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $1.4 million, or $0.03 per basic and diluted share, for the first quarter of 2023, compared to net loss of $3.4 million, or $0.08 per share, for the first quarter of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PUMA BIOTECHNOLOGY, INC. reported full year 2023 results: revenue $205 - $210 million, net income $20 - $24 million. Guidance initiated.

Period: full year 2023
Revenue: $205 - $210 million
Net income: $20 - $24 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Second Quarter 2023 Full Year 2023 Net Product Revenue $47 - $50 million $205 - $210 million Royalty Revenue $2 - $3 million $25 - $30 million Net Income/(Loss) $0 - $1.5 million $20 - $24 million Gross to Net Adjustment 20% - 21% 19% - 20%

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PUMA BIOTECHNOLOGY, INC. reported second quarter 2023 results: revenue $47 - $50 million, net income $0 - $1.5 million. Guidance initiated.

Period: second quarter 2023
Revenue: $47 - $50 million
Net income: $0 - $1.5 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Second Quarter 2023 Full Year 2023 Net Product Revenue $47 - $50 million $205 - $210 million Royalty Revenue $2 - $3 million $25 - $30 million Net Income/(Loss) $0 - $1.5 million $20 - $24 million Gross to Net Adjustment 20% - 21% 19% - 20%

View on SEC.gov

Browse all earnings releases →

PUMA BIOTECHNOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-012576

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.